文献速递肝病

非酒精性脂肪性肝病肝硬化检测策略在美国医疗体系下的成本效益分析

Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-11

该研究建立决策模型,比较9种单一或联合策略(包括FIB-4、VCTE、MRE和肝活检)在NAFLD患者中检测肝硬化的成本效益。在肝硬化患病率0.27%、2%和4%时,FIB-4联合VCTE每人成本最低且诊断准确性最高;FIB-4联合MRE的ICER低于FIB-4联合肝活检。结论认为FIB-4序贯VCTE、MRE或肝活检均能高准确度、低成本地检测肝硬化。

要点

  • FIB-4联合VCTE在三种患病率下成本最低且准确性最高。
  • FIB-4联合MRE的ICER低于FIB-4联合肝活检。
  • 若避免肝活检,FIB-4联合VCTE与联合MRE准确性相似。

核心结论

  • 在美国医疗体系下,FIB-4序贯VCTE、MRE或肝活检均能以高准确度和低成本检测NAFLD患者的肝硬化。
  • 与成本最低的FIB-4联合VCTE相比,FIB-4联合MRE的ICER低于FIB-4联合肝活检。

研究设计与样本

  • 研究建立决策模型,量化9种单一或联合策略检测NAFLD患者肝硬化的准确性和成本。
  • 策略包括FIB-4、VCTE、MRE和肝活检,数据来自已发表文献,评估5年内的诊断准确性、成本、不良事件和肝硬化结局。
  • 针对肝硬化患病率0.27%、2%和4%计算每种策略的每患者成本、正确诊断成本和ICER。

主要发现

  • FIB-4联合VCTE在患病率0.27%、2%、4%时每人成本分别为401、690、1024美元,诊断准确性分别为89.3%、88.5%、87.5%。
  • FIB-4联合MRE每人成本分别为491、781、1114美元,诊断准确性分别为92.4%、91.6%、90.6%。
  • 与FIB-4联合VCTE相比,FIB-4联合MRE的ICER分别为2864、2918、2921美元,FIB-4联合肝活检的ICER分别为4454、5156、5956美元。
  • 若目标是避免肝活检,FIB-4联合VCTE与FIB-4联合MRE诊断准确性相似(87.5%-89.3% vs 90.6%-92.4%),但后者成本略高。

关键数值与推荐

  • FIB-4联合VCTE在患病率0.27%、2%、4%时每人成本最低(401、690、1024美元)且诊断准确性最高(89.3%、88.5%、87.5%)。
  • FIB-4联合MRE的ICER(2864、2918、2921美元)低于FIB-4联合肝活检(4454、5156、5956美元)。

临床怎么用

  • 在NAFLD患者肝硬化检测中,可优先考虑FIB-4联合VCTE作为成本最低且准确性高的策略。
  • 若需避免肝活检,FIB-4联合MRE可作为替代选择,准确性相似但成本略高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Several strategies are available for detecting cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD), but their cost effectiveness is not clear. We developed a decision model to quantify the accuracy and costs of 9 single or combination strategies, including 3 noninvasive tests (fibrosis-4 [FIB-4], vibration-controlled transient elastography [VCTE], and magnetic resonance elastography [MRE]) and liver biopsy, for the detection of cirrhosis in patients with NAFLD. METHODS: Data on the diagnostic accuracy, costs, adverse events, and cirrhosis outcomes over a 5-year period were obtained from publications. The diagnostic accuracy, per-patient cost per correct diagnosis of cirrhosis, and incremental cost-effectiveness ratios (ICERs) were calculated for each strategy for base cirrhosis prevalence values of 0.27%, 2%, and 4%. RESULTS: The combination of the FIB-4 and VCTE identified patients with cirrhosis in NAFLD populations with a 0.27%, 2%, and 4% prevalence of cirrhosis with the lowest cost per person ($401, $690, and $1024, respectively) and highest diagnostic accuracy (89.3%, 88.5%, and 87.5% respectively). The combination of FIB-4 and MRE ranked second in cost per person ($491, $781, and $1114, respectively) and diagnostic accuracy (92.4%, 91.6%, 90.6%, respectively). Compared with the combination of FIB-4 and VCTE (least costly), the ICERs were lower for the combination of FIB-4 and MRE ($2864, $2918, and $2921) than the combination of FIB-4 and liver biopsy ($4454, $5156, and $5956) at the cirrhosis prevalence values tested. When the goal was to avoid liver biopsy, FIB-4 + VCTE and FIB-4 + MRE had similar diagnostic accuracies, ranging from 87.5% to 89.3% and 90.6% to 92.4% for a cirrhosis diagnosis, respectively, although FIB-4 + MRE had a slightly higher cost. CONCLUSIONS: In our cost-effectiveness analysis based on the US health care system, we found that results from FIB-4, followed by either VCTE, MRE, or liver biopsy, detect cirrhosis in patients with NAFLD with a high level of accuracy and low cost. Compared with FIB-4 + VCTE, which was the least costly strategy, FIB-4 + MRE had a lower ICER than FIB-4 + LB.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Lou Z, Kong N, et al. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. Clin Gastroenterol Hepatol. 2020. PMID: 32289535. doi:10.1016/j.cgh.2020.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。